The pharmaceutical giant, Johnson & Johnson (JNJ), has been steadily making progress in the market but has faced several confrontations. The company's legal issues could be resolved soon. Propelled by strong sales and high institutional ownership, the company is stacking up against rivals as a potentially strong investment option.
J&J focusses on advancing healthcare through AI and is combating counterfeit medical products. The company has raised its sales outlook and was recently named among Forbes’ best employers for tech workers and to Fortune's list of America's Most Innovative Companies.
In the MedTech space, the company's VARIPULSE™ Pulsed Field Ablation Platform and DARZALEX FASPRO® / DARZALEX® have received FDA approvals, bolstering growth prospects. J&J also recently purchased medical device maker V-Wave for up to $1.7 billion.
A $700 million talc settlement has been reached with numerous US states, marking potential progress towards reconciling previous legal troubles. Further, a robust Q3 2024 earnings report with strong sales growth and an EPS beat has further invigorated the company in the marketplace.
Johnson Johnson JNJ News Analytics from Tue, 23 Jan 2024 08:00:00 GMT to Sat, 09 Nov 2024 11:34:38 GMT - Rating 8 - Innovation 9 - Information 7 - Rumor 4
